Table 1.

Characteristics of PCa cases and controls in the PHS

Case-control analysisCases (n = 1,286)Controls (n = 1,267)
Age (y) at study onset, mean ± SD57.9 ± 8.457.5 ± 8.4
Gleason score, n (%)
    2-6608 (52.1)
    7388 (33.2)
    8-10172 (14.7)
Clinical stage, n (%)
    T1, T21,079 (88.4)
    T3, T4, N1, M1142 (11.6)
Selenium (μg/g), median (10th-90th)(n = 782)(n = 540)
0.109 (0.086-0.133)0.110 (0.088-0.134)
Case-only analysisCases (n = 1,331)
Age at diagnosis (y), mean ± SD70.1 ± 7.4
Deaths/metastases due to PCa, n (%)178 (13.4)
Diagnosis to PCa death/mets, median years (range)5.4 (0.3-17.9)
Follow-up time to censored, median years (range)10.0 (0.01-25.2)
Antioxidant score distribution,* n (%)(n = 744)
    3-5140 (18.8)
    6-7233 (31.3)
    8-9226 (30.4)
    10-12145 (19.5)
  • *Antioxidant score is the sum of the quartiles of plasma selenium, α-tocopherol, and lycopene.